Equity Overview
Price & Market Data
Price: $5.47
Daily Change: -$0.225 / 4.12%
Daily Range: $5.41 - $5.69
Market Cap: $518,523,104
Daily Volume: 277,826
Performance Metrics
1 Week: -2.39%
1 Month: -15.12%
3 Months: 1.80%
6 Months: 52.69%
1 Year: 375.3%
YTD: 4.32%
Company Details
Employees: 40
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
Zura Bio Limited, a clinical-stage biotechnology company, develops medicines for autoimmune and inflammatory disorders in the United States. The company develops Tibulizumab, a humanized IgG4 single-chain variable fragment bispecific antibody engineered to bind and neutralize both IL-17A and BAFF within a single therapeutic molecule, which is in Phase 2 clinical trial development. It also develops Torudokimab (ZB-880), a fully human immunoglobulin G4 monoclonal antibody targeting interleukin-33 that has completed Phase 1 clinical studies; and Crebankitug (ZB-168), a fully human immunoglobulin G1 monoclonal antibody targeting interleukin-7 receptor alpha that has completed Phase 1 clinical studies. Zura Bio Limited was founded in 2022 and is headquartered in Henderson, Nevada.